A genomic polymorphism within the tumor necrosis factor locus influences plasma tumor necrosis factor-α concentrations and outcome of patients with severe sepsis

Critical Care Medicine

Volumn 24, Issue 3, 1996, Pages 381-384

  Stüber, Frank ^a   Petersen, Marc ^a   Bokelmann, Frank ^a   Schade, Ulrich ^b  

^a UNIVERSITY OF KIEL   (Germany)

^b UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

critical illness; cytokines, tumor necrosis factor ; infection; patient outcome assessment; polymorphism; sepsis; tumor necrosis factor

Indexed keywords

TUMOR NECROSIS FACTOR;

ALLELISM; ARTICLE; BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; CRITICAL ILLNESS; GENETIC POLYMORPHISM; HUMAN; INFECTION; MULTIPLE ORGAN FAILURE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SEPSIS; TREATMENT OUTCOME;

ACUTE DISEASE; ALLELES; GENOME, HUMAN; GENOTYPE; HUMANS; MOLECULAR SEQUENCE DATA; MULTIPLE ORGAN FAILURE; POLYMORPHISM, GENETIC; PROSPECTIVE STUDIES; SEPSIS;

EID: 0029922017     PISSN: 00903493     EISSN: None     Source Type: Journal    
DOI: 10.1097/00003246-199603000-00004     Document Type: Article

References (17)

1. Members of the American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference Committee: American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: Definitions for sepsis and organ failure and guidelines for the use of innovative therapy in sepsis. Crit Care Med 1992; 20:864-874
2. Strieter RM, Kunkel SL, Bone RC: Role of tumor necrosis factor-alpha in disease states and inflammation. Crit Care Med 1993; 21:S447-S463
3. Waage A, Brandtzaeg P, Halstensen A, et al: The complex pattern of cytokines in serum from patients with meningococcal septic shock. J Exp Med 1989; 169:333-338
4. Debets JM, Kampmeijer R, van-der-Linden M, et al: Plasma tumor necrosis factor and mortality in critically ill septic patients. Crit Care Med 1989; 17: 489-494
5. Damas P, Reuter A, Gysen P, et al: Tumor necrosis factor and interleukin-1 serum levels during severe sepsis in humans. Crit Care Med 1989; 17:975-978
6. Dofferhoff AS, Bom VJ, de-Vries-Hospers HG, et al: Patterns of cytokines, plasma endotoxin, plasminogen activator inhibitor, and acute-phase proteins during the treatment of severe sepsis in humans. Crit Care Med 1992; 20: 185-192
7. Wherry JC, Pennington JE, Wenzel, RP: Tumor necrosis factor and the therapeutic potential of anti-tumor necrosis factor antibodies. Crit Care Med 1993; 21:S436-S440
8. Fisher CJ Jr, Opal SM, Dhainaut J-F, et al: Influence of an anti-tumor necrosis factor monoclonal antibody on cytokine levels in patients with sepsis. Crit Care Med 1993; 21:318-327
9. Nedwin GE, Naylor SL, Sakaguchi AY, et al: Human lymphotoxin and tumor necrosis factor genes: Structure, homology and chromosomal localization. Nucleic Acids Res 1985; 13:6361-6373
10. Pociot F, Briant L, Jongeneel CV, et al: Association of tumor necrosis factor (TNF) and class II major histocompatibility complex alleles with the secretion of TNF-alpha and TNF-beta by human mononuclear cells: A possible link to insulin-dependent diabetes mellitus. Eur J Immunol 1993; 23:224-231
11. Fugger L, Morling N, Ryder P, et al: NcoI restriction fragment length polymorphism (RFLP) of the tumor necrosis factor (TNFa) region in four autoimmune diseases. Tissue Antigens 1989; 34:17-22
12. Sambrook J, Fritsch EF, Maniatis T: Molecular Cloning. A Laboratory Manual. Second Edition. New York, Cold Spring Harbor Laboratory Press, 1989, pp 14-21
13. 32P-based hybridizations. Anal Biochem 1993; 210:235-244
14. Goris RJ, te-Boekhorst TP, Nuytinck JK, et al: Multiple-organ failure: Generalized autodestructive inflammation? Arch Surg 1985; 120:1109-1115
15. Fugger L, Morling N, Ryder LP, et al: Nco I restriction fragment length polymorphism (RFLP) of the tumor necrosis factor (TNFa) region in primary biliary cirrhosis and in healthy Danes. Scand J Immunol 1989; 30:185-189
16. Molvig J, Pociot F, Baek L, et al: Monocyte function in IDDM patients and healthy individuals. Scand J Immunol 1990; 31:297-306
17. Opal S: Anti-TNF therapy in sepsis. Third International Conference on the Immune Consequences of Sepsis, Trauma and Shock, Munich, March 2-5, 1994